Understanding The Biology and Potential Drug Targets of Carbonic Anhydrase VA

Target Name: CA5A

NCBI ID: G763

CA5A

Understanding The Biology and Potential Drug Targets of Carbonic Anhydrase VA

Carbonic anhydrase VA (CA5A), also known as mitochondrial precursor, is a protein that is expressed in high levels in the liver and other tissues of the body. It plays a crucial role in the metabolism of fatty acids, particularly the triacylglycerols (triglycerides) that are derived from fatty acids. The liver is the primary site of fat metabolism in the body, and the levels of CA5A in the liver are highly sensitive to changes in the levels of fatty acids.

CA5A has been identified as a potential drug target and a biomarker for several diseases, including obesity, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease. In this article, we will discuss the biology and pathology of CA5A, its potential drug targets, and its potential as a biomarker for disease.

The biology and pathology of CA5A

CA5A is a 26-kDa protein that is expressed in high levels in the liver, skeletal muscle, and other tissues of the body. It is a member of the superfamily of cDNA-containing proteins, which are characterized by the presence of a cytoplasmic tail and a transmembrane domain. The cytoplasmic tail of CA5A is composed of 120 amino acids and is involved in the regulation of cellular processes, such as cell adhesion, migration, and invasion.

In addition to its cytoplasmic tail, CA5A has a transmembrane domain that is involved in the regulation of protein synthesis and localization to the plasma membrane. The transmembrane domain of CA5A consists of 12 amino acids and is involved in the formation of a complex with the cytoplasmic tail.

The biology of CA5A is closely related to the metabolism of fatty acids. Fatty acids are essential for cellular survival and growth, and the levels of fatty acids in the body are tightly regulated by multiple enzymes, including enzymes that are dependent on CA5A.

In the liver, CA5A is involved in the metabolism of fatty acids, particularly triacylglycerols. Triacylglycerols are derived from fatty acids and are expressed in high levels in the liver, where they are metabolized by enzymes that are dependent on CA5A. The metabolism of triacylglycerols is a critical component of the liver's ability to remove excess fat from the body.

In addition to its role in fatty acid metabolism, CA5A is also involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. CA5A has been shown to be involved in the regulation of cell adhesion, as well as the migration and invasion of cancer cells.

The pathology of CA5A is closely related to its role in the regulation of fatty acid metabolism and cellular processes. Obesity, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease are all associated with disruptions in the regulation of fatty acids, and CA5A may be a potential drug target and biomarker for these diseases.

Potential drug targets for CA5A

The potential drug targets for CA5A are numerous and varied. One of the primary targets of CA5A is the regulation of fatty acid metabolism, including the metabolism of triacylglycerols. Drugs that target CA5A have been shown to be effective in reducing the levels of triacylglycerols in the liver, leading to improvements in the symptoms of obesity and non-alcoholic fatty liver disease (NAFLD) (9,10).

Another potential drug target for CA5A is its role in the regulation of cell adhesion and migration. CA5A has been shown to be involved in the regulation of cell adhesion and has been implicated in the development of cancer. Drugs that target

Protein Name: Carbonic Anhydrase 5A

Functions: Mitochondrial carbonic anhydrase that catalyzes the reversible conversion of carbon dioxide to bicarbonate/HCO3 (PubMed:8356065, PubMed:24530203). Mitochondria are impermeable to HCO3, and thus this intramitochondrial carbonic anhydrase is pivotal in providing HCO3 for multiple mitochondrial enzymes that catalyze the formation of essential metabolites of intermediary metabolism in the urea and Krebs cycles (PubMed:24530203)

The "CA5A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CA5A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets